Latest articles from Renal and Urology News Diabetes
Kidney Failure Risk Minimal Following Diabetes Diagnosis
In a Finnish study, the cumulative risk for end-stage renal disease among patients with newly diagnosed with type 2 diabetes was less than 1% at 20 years.
Treating Albuminuria Reduces CV Events, Death in Type 2 Diabetes
Suppressing albuminuria should be an important target of therapy, according to investigators.
SGLT2 Inhibitors and Urinary Tract Infections: What's the Link?
For this study, the authors identified randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.
Noninferior CV Outcomes for Linagliptin in T2D With High CV, Renal Risk
Linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk for a composite cardiovascular or renal outcome over a median 2.2 years.
SGLT2 Inhibitors May Reduce CV, Renal Risks in Type 2 Diabetes
SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.
Bardoxolone Methyl Leads to Weight Loss in T2D With Concurrent Chronic Kidney Disease
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
TRT May Reduce Mortality Without Improving CV Health in Diabetes
In a study, reduced mortality was found among TRT users with type 2 diabetes after adjustment for cardiovascular risk factors.
Canagliflozin Approved to Reduce Risk of Major Adverse Cardiovascular Events
The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.
Canagliflozin Ups Survival in Type 2 Diabetes With Macroalbuminuria
Canagliflozin vs placebo is associated with increased survival and renal outcomes in patients with type 2 diabetes and macroalbuminuria.
Sitagliptin Better for Glycemic Control in T2D With Renal Impairment
Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.
Diabetes Population Has Higher Incidences of Bladder, Kidney Cancer
Finnish study of individuals with type 2 diabetes reveals a 17% and 42% higher incidence of bladder and kidney cancer, respectively, compared with the general population.
Diabetes Develops At a Higher Rate in the CKD Population
New study reveals a type 2 diabetes incidence rate of 17.81 cases per 1000 person-years, a rate much higher than in the general population.
High Phosphorus Predicts Diabetic Nephropathy Progression
Highest vs lowest quartile of serum phosphorus is independently associated with a nearly 3-fold increased risk of diabetic nephropathy progression.
Cardiovascular Event Rates Vary by Kidney Failure Cause
Among US dialysis patients, cardiovascular event rates are highest in those with diabetic nephropathy and lowest among those with IgA nephropathy.
Canagliflozin Trial for T2D, CKD Halted Due to Positive Results
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
Feed Fetched by RSS Dog.